DDrare: Database of Drug Development for Rare Diseases

210. 単心室症
［臨床試験数：47，薬物数：54（DrugBank：23），標的遺伝子数：32，標的パスウェイ数：66］

Searched query = "Single Ventricle", "SV", "Single ventricle heart defect", "Univentricular heart", "UVH", "Single ventricular circulation syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = ACETYLSALICYLIC ACID; ACT-064992; Acetylsalicylic acid; Administration of an ACE-inhibitor or not; Aesculus Hippocastanum / Horse Chestnut; Ambrisentan; Arginine; Aspirin; Autologous Tissue-Engineered Vascular Graft; BAY 59-7939; Bosentan; Carvedilol; Colchicine; Digoxin; Enalapril; Eplerenone; Horse chestnut; JNJ-39039039; Liothyronine; Liothyronine I 131; MACITENTAN; MPC; MZ101; Macitentan; Milk; Mysildecard; Mysildecard 20 mg; Nitric Oxide; Normal Saline; ODSH at 0.125 mg/kg/h; ODSH at 0.250 mg/kg/h; ODSH at 0.375 mg/kg/h; Opsumit; Opsumit®; Other: Human Milk Derived Fortifier; Other: Human/Bovine Milk; RIVAROXABAN; Rexlemestrocel-L; Rivaroxaban; SCRM001_TEVG; Sildenafil; Sildenafil by injection; Spironolactone; Spironolactone (drug); Sugar pill; Tadalafil; Tadalafil Citrate; Tracleer; Treprostinil; Udenafil; Vasopressin; Vasopressin, Arginine; Vitamin C; Xarelto

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2015-002610-76-BE (EUCTR)	21/09/2016	18/07/2016	A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy of Rivaroxaban for Thromboprophylaxis in Pediatric Subjects 2 to 8 Years of Age after the Fontan Procedure	A Prospective, Open-Label, Active-Controlled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy of Rivaroxaban for Thromboprophylaxis in Pediatric Subjects 2 to 8 Years of Age after the Fontan Procedure	thromboprophylaxis MedDRA version: 19.0;Level: LLT;Classification code 10040729;Term: Single ventricle;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]	Product Name: Xarelto Product Code: JNJ-39039039; BAY 59-7939 INN or Proposed INN: RIVAROXABAN Trade Name: Aspirin Product Name: acetylsalicylic acid INN or Proposed INN: ACETYLSALICYLIC ACID	Janssen-Cilag International N.V	NULL	Not Recruiting			Female: yes Male: yes	100	Phase 3	United States;Thailand;Spain;United Kingdom;France;Mexico;Canada;Argentina;Belgium;Brazil;Malaysia;Australia;Netherlands;China;Japan;Korea, Republic of

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2015-002610-76-BE
(EUCTR)

21/09/2016

18/07/2016

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy of Rivaroxaban for Thromboprophylaxis in Pediatric Subjects 2 to 8 Years of Age after the Fontan Procedure

A Prospective, Open-Label, Active-Controlled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy of Rivaroxaban for Thromboprophylaxis in Pediatric Subjects 2 to 8 Years of Age after the Fontan Procedure

thromboprophylaxis
MedDRA version: 19.0;Level: LLT;Classification code 10040729;Term: Single ventricle;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]

Product Name: Xarelto
Product Code: JNJ-39039039; BAY 59-7939
INN or Proposed INN: RIVAROXABAN
Trade Name: Aspirin
Product Name: acetylsalicylic acid
INN or Proposed INN: ACETYLSALICYLIC ACID

Janssen-Cilag International N.V

NULL

Not Recruiting

Female: yes
Male: yes

100

Phase 3

United States;Thailand;Spain;United Kingdom;France;Mexico;Canada;Argentina;Belgium;Brazil;Malaysia;Australia;Netherlands;China;Japan;Korea, Republic of